Pharmacovigilance is increasingly adopted across pharmaceutical companies, regulatory bodies, clinical research organizations ...

-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio ...

Nishit Agarwal exemplifies excellence in Biomedical AI and Signal Processing with extensive experience in developing cutting-edge clinical AI solutions and biomarker development. His expertise spans ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Universal DX (“UDX”), a biotech company dedicated to transforming cancer into a curable disease by detecting it early, today announced closure of the Series B which ...